Medical research

Researchers find a new pathological mediator of ALS

A research collaboration based in Japan has found a new pathological mediator of amyotrophic lateral sclerosis (ALS), which could have further implications for understanding the molecular breakdown that gives rise to the ...

Neuroscience

Could heavier folks be at lower risk for ALS?

It's not often that anything good is associated with obesity. Yet heavy folks and those who bulk up as they age may have less risk for the deadly disease amyotrophic lateral sclerosis (ALS), a new study finds.

Neuroscience

High BMI, weight gain linked to lasting decrease in ALS risk

(HealthDay)—High body mass index (BMI) and weight gain are associated with a reduced long-term risk for amyotrophic lateral sclerosis (ALS), according to a study published online June 26 in Neurology.

Medical research

Experimental treatment slows prion disease, extends life of mice

Scientists using an experimental treatment have slowed the progression of scrapie, a degenerative central nervous disease caused by prions, in laboratory mice and greatly extended the rodents' lives, according to a new report ...

Neuroscience

ALS patients may benefit from more glucose

Increased glucose, transformed into energy, could give people with amyotrophic lateral sclerosis, or ALS, improved mobility and a longer life, according to new findings by a University of Arizona-led research team.

page 1 from 23

Amyotrophic lateral sclerosis (ALS), also referred to as Lou Gehrig's disease in American English and Motor Neurone Disease in British English, is a form of Motor Neuron Disease caused by the degeneration of upper and lower neurons, located in the ventral horn of the spinal cord and the cortical neurons that provide their efferent input. The condition is often called Lou Gehrig's disease in North America, after the New York Yankees baseball player who was diagnosed with the disease in 1939. The disorder is characterized by rapidly progressive weakness, muscle atrophy and fasciculations, spasticity, dysarthria, dysphagia, and respiratory compromise. Sensory function generally is spared, as is autonomic and oculomotor activity. ALS is a progressive, fatal, neurodegenerative disease with most affected patients dying of respiratory compromise and pneumonia after 2 to 3 years; although some perish within a year from the onset of symptoms, and occasional individuals have a more indolent course and survive for many years.

This text uses material from Wikipedia licensed under CC BY-SA